India opens the door to partners
20 December, 2005 by Iain ScottKiran Mazumdar-Shaw told AusBiotech 2005 about opportunities for Australian biotech to work with India.
Grain Biotech harvests first salt-resistant wheat crop
19 December, 2005 by Graeme O'NeillPerth agbiotech company Grain Biotech Australia harvested its first trial crop of genetically modified, salt-tolerant wheat this month, grown in salt-affected farmland near Corrigin, in Western Australia.
Australian government to stockpile Relenza
19 December, 2005 by Ruth BeranThe Commonwealth government has confirmed that it will add 1.8 million courses of Relenza to the National Medical Stockpile in preparation for a possible influenza pandemic.
GroPep completes final malaria vaccine milestone
19 December, 2005 by Ruth BeranAdelaide-based biotech GroPep (ASX:GRO) has completed the manufacture of two vaccine antigens for the Bill and Melinda Gates Foundation-funded Malaria Vaccine Initiative (MVI).
Pharmaxis touts progress in cystic fibrosis study
19 December, 2005 by Ruth BeranSydney-based drug developer Pharmaxis (ASX:PXS, Nasdaq:PXSL) has begun the dosing phase of its phase II clinical trial in patients with cystic fibrosis.
Novogen winds up probe into proxy votes
19 December, 2005 by Ruth BeranCancer drug developer Novogen (ASX:NRT, NASDAQ:NVGN) has concluded its investigation into the reasons why there was an overwhelming majority of proxies against the company's remuneration report.
Agenix CEO Home resigns
16 December, 2005 by Ruth BeranDonald Home has resigned as CEO and managing director of Brisbane-based Agenix (ASX:AGX, NASDAQ:OTC:AGXLY) after four and a half years with the company.
CogState, Pfizer sign development deal
16 December, 2005 by Helen SchullerCogState (ASX:CGS) has signed an agreement with Pfizer worth up to AUD$1.28 million over three years to support the development of the Melbourne-based company's cognitive test portfolio.
Biosignal awarded $1.5m grant
16 December, 2005 by Ruth BeranSydney antimicrobial developer Biosignal (ASX:BOS) has been awarded a AUD$1.5 million Commonwealth government grant to develop new antibacterial coatings for medical implants and devices.
Agbiotech's field of opportunity
16 December, 2005 by Iain ScottIn many places in the world, 'biotechnology' only means agricultural biotech. The same can't be said in Australia, where GM technology is a dirty word. But could economics and technology force Australia to change its views on biotech crops to keep up with the rest of the world?
Peplin to raise $10 million for skin cancer trial
15 December, 2005 by Helen SchullerPeplin (ASX:PEP) will raise AUD$10 million through a placement to fund phase IIb clinical trials of its lead product, PEP005 Topical, in actinic keratosis (AK), also known as solar keratosis, a skin condition which can develop into skin cancer.
Biota to collaborate with US firm MedImmune
15 December, 2005 by Ruth BeranMelbourne-based Biota Holdings (ASX:BTA) has entered into a licensing and collaboration agreement with US company MedImmune (Nasdaq:MEDI) to develop and commercialise Biota's small molecule compounds for the prevention and treatment of respiratory syncytial virus (RSV) infection.
Pharmaxis enrols first phase III Aridol patients
14 December, 2005 by Helen SchullerSydney-based drug developer Pharmaxis (ASX:PXS) has enrolled the first patients in a US-based phase III trial of its asthma diagnostic and treatment management tool Aridol -- the first of three phase III clinical trials the company is planning to undertake in 2006.
Imugene partners with Teva to develop poultry vaccine
13 December, 2005 by Ruth BeranAnimal health biotech Imugene (ASX:IMU) has signed an agreement with Abic Biological Laboratories Teva, the animal health division of Israeli-based Teva Pharmaceutical Industries, to develop and evaluate a new vaccine for the prevention of poultry coccidiosis.
GTG celebrates win over Applera in patent battle
12 December, 2005 by Graeme O'NeillAn elated Dr Mervyn Jacobson, CEO of Genetic Technologies (ASX:GTG, NASDAQ:GENE), flew back to Melbourne from San Francisco this morning after slaying his company's most reluctant dragon, giant US rival Applera.
